Comparison of the efficacy and total cost of peripheral blood stem cell collections in allogeneic donors using either filgrastim (Neupogen®) or filgrastim aafi (Nivestym®)

IF 1.2 4区医学 Q4 HEMATOLOGY

Transfusion and Apheresis Science Pub Date : 2025-06-01 DOI:10.1016/j.transci.2025.104113

Chuying Su , Leon L. Su , Kristin L. Gray , Carrie E. Karlene , Theresa N. Kinard , Lance A. Williams III

引用次数: 0

Abstract

This retrospective study evaluated the efficacy and total cost of switching from filgrastim (Neupogen) to its biosimilar, filgrastim-aafi (Nivestym), for allogeneic peripheral blood stem cell collection (PBSCC). Among 127 donors, Nivestym and Neupogen showed comparable mobilization outcomes, achieving similar CD34 + cell counts and one-day collection success rates for ≥ 2.0 × 10⁶ and ≥ 4.0 × 10⁶ CD34 + cells/kg recipient weight. Nivestym offered significant reduction in total cost, with an average of $5171.92 versus $6288.76 (p < 0.0001). These findings support Nivestym as a viable alternative, highlighting the importance of evaluating both clinical outcomes and financial implications for biosimilar adoption.

查看原文本刊更多论文

非格司汀（Neupogen®）和非格司汀aafi （Nivestym®）异体供体外周血干细胞采集的疗效和总成本比较

这项回顾性研究评估了从非格司汀（Neupogen）转向其生物仿制药非格司汀-aafi （Nivestym）用于异基因外周血干细胞采集（PBSCC）的疗效和总成本。在127个捐助者、Nivestym和Neupogen显示类似的动员效果,实现类似CD34 + 细胞计数和一天收集的成功率≥2.0  × 10⁶≥4.0  ×10 ⁶CD34 + 细胞/公斤重量。Nivestym显著降低了总成本，平均为5171.92美元，而不是6288.76美元（p <； 0.0001）。这些发现支持Nivestym作为一种可行的替代方案，强调了评估临床结果和对生物类似药采用的财务影响的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion and Apheresis Science 医学-血液学

CiteScore

3.60

自引率

5.30%

发文量

181

审稿时长

42 days

期刊介绍： Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.